Arkolith/Insider Trading/ATHA/Form 4

Litton Mark James

President and CEO, DirectorAthira Pharma, Inc. (ATHA) · full profile →Form 4 · filed Jul 2, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$7K
Net Open-Market Flow
-$7K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 1, 2025Sell(S)25K$0.29$7K326K
Jun 30, 2025Option exercise(M)108K—$0351K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 30, 2025Option exercise(M)108K—$0108K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-25-019069) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML